PMC:7195088 / 33273-33620 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T43","span":{"begin":321,"end":327},"obj":"Body_part"}],"attributes":[{"id":"A43","pred":"fma_id","subj":"T43","obj":"http://purl.org/sig/ont/fma/fma228738"}],"text":"Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or chloroquine in patients with COVID-19 pneumonia. Open-label RCT (NCT04286503, not yet recruiting). Primary endpoints: (a) fever to normal time (follow-up 30 days); (b) pulmonary inflammation resolution time (follow-up 30 days); (c) negative conversion of throat swab RT-PCR at EOT."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T27","span":{"begin":321,"end":327},"obj":"Body_part"}],"attributes":[{"id":"A27","pred":"uberon_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/UBERON_0000341"}],"text":"Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or chloroquine in patients with COVID-19 pneumonia. Open-label RCT (NCT04286503, not yet recruiting). Primary endpoints: (a) fever to normal time (follow-up 30 days); (b) pulmonary inflammation resolution time (follow-up 30 days); (c) negative conversion of throat swab RT-PCR at EOT."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T31","span":{"begin":104,"end":113},"obj":"Phenotype"},{"id":"T32","span":{"begin":188,"end":193},"obj":"Phenotype"}],"attributes":[{"id":"A31","pred":"hp_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A32","pred":"hp_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/HP_0001945"}],"text":"Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or chloroquine in patients with COVID-19 pneumonia. Open-label RCT (NCT04286503, not yet recruiting). Primary endpoints: (a) fever to normal time (follow-up 30 days); (b) pulmonary inflammation resolution time (follow-up 30 days); (c) negative conversion of throat swab RT-PCR at EOT."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T171","span":{"begin":95,"end":103},"obj":"Disease"},{"id":"T172","span":{"begin":104,"end":113},"obj":"Disease"},{"id":"T173","span":{"begin":244,"end":256},"obj":"Disease"}],"attributes":[{"id":"A171","pred":"mondo_id","subj":"T171","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A172","pred":"mondo_id","subj":"T172","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A173","pred":"mondo_id","subj":"T173","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"}],"text":"Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or chloroquine in patients with COVID-19 pneumonia. Open-label RCT (NCT04286503, not yet recruiting). Primary endpoints: (a) fever to normal time (follow-up 30 days); (b) pulmonary inflammation resolution time (follow-up 30 days); (c) negative conversion of throat swab RT-PCR at EOT."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T186","span":{"begin":120,"end":125},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T187","span":{"begin":185,"end":186},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T188","span":{"begin":231,"end":232},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"}],"text":"Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or chloroquine in patients with COVID-19 pneumonia. Open-label RCT (NCT04286503, not yet recruiting). Primary endpoints: (a) fever to normal time (follow-up 30 days); (b) pulmonary inflammation resolution time (follow-up 30 days); (c) negative conversion of throat swab RT-PCR at EOT."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T450","span":{"begin":29,"end":48},"obj":"Chemical"},{"id":"T451","span":{"begin":29,"end":38},"obj":"Chemical"},{"id":"T452","span":{"begin":39,"end":48},"obj":"Chemical"},{"id":"T453","span":{"begin":52,"end":62},"obj":"Chemical"},{"id":"T454","span":{"begin":66,"end":77},"obj":"Chemical"},{"id":"T455","span":{"begin":120,"end":125},"obj":"Chemical"}],"attributes":[{"id":"A450","pred":"chebi_id","subj":"T450","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A451","pred":"chebi_id","subj":"T451","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A452","pred":"chebi_id","subj":"T452","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A453","pred":"chebi_id","subj":"T453","obj":"http://purl.obolibrary.org/obo/CHEBI_134730"},{"id":"A454","pred":"chebi_id","subj":"T454","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A455","pred":"chebi_id","subj":"T455","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"}],"text":"Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or chloroquine in patients with COVID-19 pneumonia. Open-label RCT (NCT04286503, not yet recruiting). Primary endpoints: (a) fever to normal time (follow-up 30 days); (b) pulmonary inflammation resolution time (follow-up 30 days); (c) negative conversion of throat swab RT-PCR at EOT."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T12","span":{"begin":244,"end":256},"obj":"http://purl.obolibrary.org/obo/GO_0006954"}],"text":"Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or chloroquine in patients with COVID-19 pneumonia. Open-label RCT (NCT04286503, not yet recruiting). Primary endpoints: (a) fever to normal time (follow-up 30 days); (b) pulmonary inflammation resolution time (follow-up 30 days); (c) negative conversion of throat swab RT-PCR at EOT."}

{"project":"LitCovid-sentences","denotations":[{"id":"T268","span":{"begin":115,"end":164},"obj":"Sentence"},{"id":"T269","span":{"begin":165,"end":347},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or chloroquine in patients with COVID-19 pneumonia. Open-label RCT (NCT04286503, not yet recruiting). Primary endpoints: (a) fever to normal time (follow-up 30 days); (b) pulmonary inflammation resolution time (follow-up 30 days); (c) negative conversion of throat swab RT-PCR at EOT."}